Pacific Biosciences of California, Inc. (PACB) Posts Q3 EPS Loss of $0.54, Sales Top Expectations

Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q3 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $9.73 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• High Tide Inc. (HITI) Tops Q2 EPS by 11c
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh